Corxel Secures FDA IND Clearance for CX11 Phase 2 Trial in Type 2 Diabetes
Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared...
CORXEL Pharmaceuticals
Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development
China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...
Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval
China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...
Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage
China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...
Sanofi and Corxel Pharmaceuticals Partner for Aficamten in Greater China Rights
Global healthcare leader Sanofi (NASDAQ: SNY) and China-based Corxel Pharmaceuticals (CORXEL), formerly known as Ji...
Grand Pharmaceutical Group Secures Licensing Agreement for CORXEL’s Nasal Sprays in Greater China
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with...
CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...
CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...
Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment
CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved...
CDE Lists Five Drugs and One Companion Diagnostic for Priority Review Status
The Center for Drug Evaluation (CDE) has indicated on its website that five investigational drugs...
CORXEL Gets CDE Green Light for Phase III Aficamten Study in nHCM
CORXEL, formerly known as Ji Xing Pharmaceuticals, a China-based pharmaceutical company, has announced that it...
CORXEL Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a...
CORXEL Partners with WuXi STA for Sterile Nasal Spray Production
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...
CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...
Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...